Indoles - Gut bacteria metabolites of tryptophan with pharmacotherapeutic potential

Current Drug Metabolism

Volumn 19, Issue 10, 2018, Pages 883-890

  Konopelski, Piotr ^a   Ufnal, Marcin ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Gut microbiota; Indoles; Indoxyl sulfate; Serotonin; Tryptophan

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ESSENTIAL AMINO ACID; INDICAN; INDOLE; INDOLE DERIVATIVE; INDOLEACETIC ACID; INDOLEPROPIONIC ACID; INTERLEUKIN 10; INTERLEUKIN 8; KYNURENIC ACID; MELATONIN; SEROTONIN; SKATOLE; TRYPTAMINE; TRYPTOPHAN; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CHRONIC KIDNEY FAILURE; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; EMPHYSEMA; ENDOTHELIAL PROGENITOR CELL; FIBROSING ALVEOLITIS; FLUOROMETRY; GLUCOSE INTOLERANCE; HARTNUP DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEMOSTASIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; HYPERTROPHY; INFLAMMATION; INTESTINE FLORA; KIDNEY TRANSPLANTATION; LUNG EDEMA; MENTAL DISEASE; METABOLIC DISORDER; NONHUMAN; REVIEW; SCHIZOPHRENIA; THROMBOSIS; TRYPTOPHAN METABOLISM; ANIMAL; HUMAN; METABOLISM;

ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; INDOLES; TRYPTOPHAN;

EID: 85053681460     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200219666180427164731     Document Type: Review

References (118)

1. Hussack, G.; Tanha, J. An update on antibody-based immunothera-pies for Clostridium difficile infection. Clin. Exp. Gastroenterol., 2016, 9, 209-224.
2. Pigneur, B.; Sokol, H. Fecal microbiota transplantation in inflammatory bowel disease: The quest for the holy grail. Mucosal Immunol., 2016, 9(6), 1360-1365.
3. Jayasinghe, T.N.; Chiavaroli, V.; Holland, D.J.; Cutfield, W.S.; O'Sullivan, J. M. The new era of treatment for obesity and metabolic disorders: Evidence and expectations for gut microbiome transplantation. Front. Cell Infect. Microbiol., 2016, 6, 15.
4. Rossen, N.G.; MacDonald, J.K.; De Vries, E.M.; D'Haens, G.R.; De Vos, W.M.; Zoetendal, E.G.; Ponsioen, C.Y. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J. Gastroenterol., 2015, 21(17), 5359-5371.
5. Sabat, A.J.; Van Zanten, E.; Akkerboom, V.; Wisselink, G.; van Slochteren, K.; de Boer, R.F.; Hendrix, R.; Friedrich, A.W.; Rossen, J.W.A.; Kooistrasmid, A. Targeted next-generation sequencing of the 16S-23S rRNA region for culture-independent bacterial identification-increased discrimination of closely related species. Sci. Rep., 2017, 7(1), 3434.
6. Nowinski, A.; Ufnal, M. Gut bacteria-derived molecules as mediators and markers in cardiovascular diseases. The role of the gut-blood barrier. Kardiol. Pol., 2018 76(2), 320-327.
7. Degnan, P.H.; Taga, M.E.; Goodman, A.L. Vitamin B12 as a modulator of gut microbial ecology. Cell Metab., 2014, 20(5), 769-778.
8. Zhang, Y.J.; Li, S.; Gan, R.Y.; Zhou, T.; Xu, D.P.; Li, H.B. Impacts of gut bacteria on human health and diseases. Int. J. Mol. Sci., 2015, 16(4), 7493-7519.
9. Ufnal, M.; Zadlo, A.; Ostaszewski, R. TMAO: A small molecule of great expectations. Nutrition, 2015, 31(11-12), 1317-1323.
10. Tomasova, L.; Konopelski, P.; Ufnal, M. Gut bacteria and hydrogen sulfide: The new old players in circulatory system homeostasis. Molecules, 2016, 21(11), 1558.
11. Tang, W.H.; Hazen, S.L. The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest., 2014, 124(10), 4204-4211.
12. Kitai, T.; Kirsop, J.; Tang, W.H. Exploring the microbiome in heart failure. Curr. Heart Fail. Rep., 2016, 13(2), 103-109.
13. Li, D.; Kirsop, J.; Tang, W.H. Listening to our gut: Contribution of gut microbiota and cardiovascular risk in diabetes pathogenesis. Curr. Diab. Rep., 2015, 15(9), 63.
14. Kim, R.B.; Morse, B.L.; Djurdjev, O.; Tang, M.; Muirhead, N.; Barrett, B.; Holmes, D.T.; Madore, F.; Clase, C.M.; Rigatto, C.; Levin, A.; Can, P.I. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int., 2016, 89(5), 1144-1152.
15. Sikora, M.; Drapala, A.; Ufnal, M. Exogenous hydrogen sulfide causes different hemodynamic effects in normotensive and hyper-tensive rats via neurogenic mechanisms. Pharmacol. Rep., 2014, 66(5), 751-758.
16. Nagpure, B.V.; Bian, J.S. Interaction of hydrogen sulfide with nitric oxide in the cardiovascular system. Oxid. Med. Cell Longev., 2016, 2016, 6904327.
17. Tomasova, L.; Dobrowolski, L.; Jurkowska, H.; Wrobel, M.; Huc, T.; Ondrias, K.; Ostaszewski, R.; Ufnal, M. Intracolonic hydrogen sulfide lowers blood pressure in rats. Nitric Oxide, 2016, 60, 50-58.
18. Meng, G.; Ma, Y.; Xie, L.; Ferro, A.; Ji, Y. Emerging role of hydrogen sulfide in hypertension and related cardiovascular diseases. Br. J. Pharmacol., 2015, 172(23), 5501-5511.
19. Szabo, C. Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. Antioxid. Redox. Signal., 2012, 17(1), 68-80.
20. Wedrychowicz, A.; Zajac, A.; Tomasik, P. Advances in nutritional therapy in inflammatory bowel diseases: Review. World J. Gastroenterol., 2016, 22(3), 1045-1066.
21. Mani, S.; Cao, W.; Wu, L.; Wang, R. Hydrogen sulfide and the liver. Nitric Oxide, 2014, 41, 62-71.
22. Fernstrom, J.D.; Wurtman, R.J.; Hammarstrom-Wiklund, B.; Rand, W.M.; Munro, H.N.; Davidson, C.S. Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: Effect of dietary protein intake. Am. J. Clin. Nutr., 1979, 32(9), 1912-1922.
23. Minet-Ringuet, J.; Le Ruyet, P.M.; Tome, D.; Even, P.C. A trypto-phan-rich protein diet efficiently restores sleep after food deprivation in the rat. Behav. Brain. Res., 2004, 152(2), 335-340.
24. Konturek, P.C.; Burnat, G.; Brzozowski, T.; Zopf, Y.; Konturek, S.J. Tryptophan free diet delays healing of chronic gastric ulcers in rat. J. Physiol. Pharmacol., 2008, 59(Suppl. 2), 53-65.
25. Kot, M.; Pilc, A.; Daniel, W.A. Simultaneous alterations of brain and plasma serotonin concentrations and liver cytochrome P450 in rats fed on a tryptophan-free diet. Pharmacol. Res., 2012, 66(4), 292-299.
26. Lamas, B.; Richard, M.L.; Leducq, V.; Pham, H.P.; Michel, M.L.; Da Costa, G.; Bridonneau, C.; Jegou, S.; Hoffmann, T.W.; Na-tividad, J.M.; Brot, L.; Taleb, S.; Couturier-Maillard, A.; Nion-Larmurier, I.; Merabtene, F.; Seksik, P.; Bourrier, A.; Cosnes, J.; Ryffel, B.; Beaugerie, L.; Launay, J. M.; Langella, P.; Xavier, R.J.; Sokol, H. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med., 2016, 22(6), 598-605.
27. Lam, V.; Su, J.; Hsu, A.; Gross, G.J.; Salzman, N.H.; Baker, J.E. Intestinal microbial metabolites are linked to severity of myocardial infarction in rats. PLoS One, 2016, 11(8), e0160840.
28. Michael, A.F.; Drummond, K.N.; Doeden, D.; Anderson, J.A.; Good, R. A. Tryptophan metabolism in man. J. Clin. Invest., 1964, 43, 1730-1746.
29. Rose, D.P. Aspects of tryptophan metabolism in health and disease: A review. J. Clin. Pathol., 1972, 25(1), 17-25.
30. Fernstrom, J.D. A Perspective on the safety of supplemental tryptophan based on its metabolic fates. J. Nutr., 2016, 146(12), 2601S-2608S.
31. Wikoff, W.R.; Anfora, A.T.; Liu, J.; Schultz, P.G.; Lesley, S.A.; Peters, E. C.; Siuzdak, G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA, 2009, 106(10), 3698-3703.
32. Palego, L.; Betti, L.; Rossi, A.; Giannaccini, G. Tryptophan biochemistry: Structural, nutritional, metabolic, and medical aspects in humans. J. Amino Acids, 2016, 2016, 8952520.
33. Robinson, B.; Fischer, E. The Fischer indole synthesis. Wiley: Chichester, New York, 1982; p. xiii, 923.
34. Dalgliesh, C.E. The relation between pyridoxin and tryptophan metabolism, studied in the rat. Biochem. J., 1952, 52(1), 3-14.
35. Graffeo, A.P.; Karger, B.L. Analysis for indole compounds in urine by high-performance liquid chromatography with fluorometric detection. Clin. Chem., 1976, 22(2), 184-187.
36. Reller, L.B.; Mirrett, S. Motility-indole-lysine medium for presumptive identification of enteric pathogens of Enterobacteriaceae. J. Clin. Microbiol., 1975, 2(3), 247-252.
37. Darkoh, C.; Chappell, C.; Gonzales, C.; Okhuysen, P. A rapid and specific method for the detection of indole in complex biological samples. Appl. Environ. Microbiol., 2015, 81(23), 8093-8097.
38. DeMoss, R.D.; Moser, K. Tryptophanase in diverse bacterial species. J. Bacteriol., 1969, 98(1), 167-171.
39. Smith, E.A.; Macfarlane, G.T. Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Mi-crob. Ecol., 1997, 33(3), 180-188.
40. Kazarinoff, M.N.; Snell, E.E. Some effects of indole on the interaction of amino acids with tryptophanase. J. Biol. Chem., 1980, 255(13), 6228-6233.
41. Banoglu, E.; Jha, G.G.; King, R.S. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet., 2001, 26(4), 235-240.
42. Banoglu, E.; King, R.S. Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur. J. Drug Metab. Pharmacokinet., 2002, 27(2), 135-140.
43. McCreanor, G.M.; Bender, D.A. The metabolism of high intakes of tryptophan, nicotinamide and nicotinic acid in the rat. Br. J. Nutr., 1986, 56(3), 577-586.
44. Donia, M.S.; Fischbach, M.A. Human microbiota. Small molecules from the human microbiota. Science, 2015, 349(6246), 1254766.
45. Patel, K.P.; Luo, F.J.; Plummer, N.S.; Hostetter, T.H.; Meyer, T.W. The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores. Clin. J. Am. Soc. Nephrol., 2012, 7(6), 982-988.
46. Vanholder, R.; De Smet, R.; Glorieux, G.; Argiles, A.; Baurmei-ster, U.; Brunet, P.; Clark, W.; Cohen, G.; De Deyn, P.P.; Dep-pisch, R.; Descamps-Latscha, B.; Henle, T.; Jorres, A.; Lemke, H.D.; Massy, Z.A.; Passlick-Deetjen, J.; Rodriguez, M.; Stegmayr, B.; Stenvinkel, P.; Tetta, C.; Wanner, C.; Zidek, W.; European Uremic Toxin Work Group. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int., 2003, 63(5), 1934-1943.
47. Mafra, D.; Lobo, J.C.; Barros, A.F.; Koppe, L.; Vaziri, N.D.; Fou-que, D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol., 2014, 9(3), 399-410.
48. Lee, J.H.; Lee, J. Indole as an intercellular signal in microbial communities. FEMS Microbiol. Rev., 2010, 34(4), 426-444.
49. Kim, J.; Park, W. Indole: A signaling molecule or a mere metabolic byproduct that alters bacterial physiology at a high concentration? J. Microbiol., 2015, 53(7), 421-428.
50. Bansal, T.; Englert, D.; Lee, J.; Hegde, M.; Wood, T.K.; Jayaraman, A. Differential effects of epinephrine, norepinephrine, and indole on Escherichia coli O157:H7 chemotaxis, colonization, and gene expression. Infect. Immun., 2007, 75(9), 4597-4607.
51. Lee, J.; Jayaraman, A.; Wood, T.K. Indole is an inter-species biofilm signal mediated by SdiA. BMC Microbiol., 2007, 7, 42.
52. Bansal, T.; Alaniz, R.C.; Wood, T.K.; Jayaraman, A. The bacterial signal indole increases epithelial-cell tight-junction resistance and attenuates indicators of inflammation. Proc. Natl. Acad. Sci. USA, 2010, 107(1), 228-233.
53. Shimada, Y.; Kinoshita, M.; Harada, K.; Mizutani, M.; Masahata, K.; Kayama, H.; Takeda, K. Commensal bacteria-dependent indole production enhances epithelial barrier function in the colon. PLoS One, 2013, 8(11), e80604.
54. Niwa, T. Indoxyl sulfate is a nephro-vascular toxin. J. Ren. Nutr., 2010, 20(5 Suppl), 2-6.
55. Niwa, T.; Ise, M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J. Lab. Clin. Med., 1994, 124(1), 96-104.
56. Wu, I. W.; Hsu, K.H.; Lee, C.C.; Sun, C.Y.; Hsu, H.J.; Tsai, C.J.; Tzen, C.Y.; Wang, Y.C.; Lin, C.Y.; Wu, M.S. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol. Dial. Transplant., 2011, 26(3), 938-947.
57. Lekawanvijit, S.; Kompa, A.R.; Manabe, M.; Wang, B.H.; Lang-ham, R.G.; Nishijima, F.; Kelly, D.J.; Krum, H. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One, 2012, 7(7), e41281.
58. Marzocco, S.; Dal Piaz, F.; Di Micco, L.; Torraca, S.; Sirico, M.L.; Tartaglia, D.; Autore, G.; Di Iorio, B. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif., 2013, 35(1-3), 196-201.
59. Nazzal, L.; Roberts, J.; Singh, P.; Jhawar, S.; Matalon, A.; Gao, Z.; Holzman, R.; Liebes, L.; Blaser, M.J.; Lowenstein, J. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease. Nephrol. Dial. Transplant., 2017, 1(11), 1809-1817.
60. Liabeuf, S.; Desjardins, L.; Massy, Z.A.; Brazier, F.; Westeel, P.F.; Mazouz, H.; Titeca-Beauport, D.; Diouf, M.; Glorieux, G.; Vanholder, R.; Jaureguy, M.; Choukroun, G. Levels of indoxyl sulfate in kidney transplant patients, and the relationship with hard outcomes. Circ. J., 2016, 80(3), 722-730.
61. Vanholder, R.; Massy, Z.; Argiles, A.; Spasovski, G.; Verbeke, F.; Lameire, N.; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant., 2005, 20(6), 1048-1056.
62. Yu, M.; Kim, Y.J.; Kang, D.H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin. J. Am. Soc. Nephrol., 2011, 6(1), 30-39.
63. Lekawanvijit, S.; Adrahtas, A.; Kelly, D.J.; Kompa, A.R.; Wang, B.H.; Krum, H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur. Heart J., 2010, 31(14), 1771-1779.
64. Huc, T.; Nowinski, A.; Drapala, A.; Konopelski, P.; Ufnal, M. Indole and indoxyl sulfate, gut bacteria metabolites of tryptophan, change arterial blood pressure via peripheral and central mechanisms in rats. Pharmacol. Res., 2018, 130, 172-179.
65. Lekawanvijit, S. Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities. Circ. J., 2015, 79(10), 2088-2097.
66. Gondouin, B.; Cerini, C.; Dou, L.; Sallee, M.; Duval-Sabatier, A.; Pletinck, A.; Calaf, R.; Lacroix, R.; Jourde-Chiche, N.; Poitevin, S.; Arnaud, L.; Vanholder, R.; Brunet, P.; Dignat-George, F.; Burtey, S. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney. Int., 2013, 84(4), 733-744.
67. Chitalia, V.C.; Shivanna, S.; Martorell, J.; Balcells, M.; Bosch, I.; Kolandaivelu, K.; Edelman, E.R. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation, 2013, 127(3), 365-376.
68. Yang, K.; Du, C.; Wang, X.; Li, F.; Xu, Y.; Wang, S.; Chen, S.; Chen, F.; Shen, M.; Chen, M.; Hu, M.; He, T.; Su, Y.; Wang, J.; Zhao, J. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood, 2017, 129(19), 2667-2679.
69. Ahmed, M.S.; Abed, M.; Voelkl, J.; Lang, F. Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate. BMC Nephrol., 2013, 14, 244.
70. Gao, C.; Ji, S.; Dong, W.; Qi, Y.; Song, W.; Cui, D.; Shi, J. Indolic uremic solutes enhance procoagulant activity of red blood cells through phosphatidylserine exposure and microparticle release. Toxins (Basel), 2015, 7(11), 4390-4403.
71. Patten, C.L.; Blakney, A.J.; Coulson, T.J. Activity, distribution and function of indole-3-acetic acid biosynthetic pathways in bacteria. Crit. Rev. Microbiol., 2013, 39(4), 395-415.
72. Brunet, P.; Gondouin, B.; Duval-Sabatier, A.; Dou, L.; Cerini, C.; Dignat-George, F.; Jourde-Chiche, N.; Argiles, A.; Burtey, S. Does uremia cause vascular dysfunction? Kidney Blood Press. Res., 2011, 34(4), 284-290.
73. Fernandez-Prado, R.; Esteras, R.; Perez-Gomez, M.V.; Gracia-Iguacel, C.; Gonzalez-Parra, E.; Sanz, A.B.; Ortiz, A.; Sanchez-Nino, M.D. Nutrients Turned into toxins: Microbiota modulation of nutrient properties in chronic kidney disease. Nutrients, 2017, 9(5), E489.
74. Dou, L.; Sallee, M.; Cerini, C.; Poitevin, S.; Gondouin, B.; Jourde-Chiche, N.; Fallague, K.; Brunet, P.; Calaf, R.; Dussol, B.; Mallet, B.; Dignat-George, F.; Burtey, S. The cardiovascular effect of the uremic solute indole-3 acetic acid. J. Am. Soc. Nephrol., 2015, 26(4), 876-887.
75. Broer, S. The role of the neutral amino acid transporter B0AT1(SLC6A19) in Hartnup disorder and protein nutrition. IUBMB Life, 2009, 61(6), 591-599.
76. Milne, M.D. Disorders of amino-acid transport. Br. Med. J., 1964, 1(5379), 327-336.
77. Milne, M.D. Hereditary abnormalities of intestinal absorption. Br. Med. Bull., 1967, 23(3), 279-284.
78. Elsden, S.R.; Hilton, M.G.; Waller, J.M. The end products of the metabolism of aromatic amino acids by Clostridia. Arch. Microbiol., 1976, 107(3), 283-288.
79. Karbownik, M.; Reiter, R.J.; Garcia, J. J.; Cabrera, J.; Burkhardt, S.; Osuna, C.; Lewinski, A. Indole-3-propionic acid, a melatonin- related molecule, protects hepatic microsomal membranes from iron-induced oxidative damage: Relevance to cancer reduction. J. Cell. Biochem., 2001, 81(3), 507-513.
80. Chyan, Y.J.; Poeggeler, B.; Omar, R.A.; Chain, D.G.; Frangione, B.; Ghiso, J.; Pappolla, M.A. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J. Biol. Chem., 1999, 274(31), 21937-21942.
81. Yokoyama, M.T.; Carlson, J.R. Microbial metabolites of tryptophan in the intestinal tract with special reference to skatole. Am. J. Clin. Nutr., 1979, 32(1), 173-178.
82. Rosenberger, R.F. Obligate anaerobes which form skatole. J. Bacteriol., 1959, 77(4), 517.
83. Karlin, D.A.; Mastromarino, A.J.; Jones, R.D.; Stroehlein, J.R.; Lorentz, O. Fecal skatole and indole and breath methane and hydrogen in patients with large bowel polyps or cancer. J. Cancer Res. Clin. Oncol., 1985, 109(2), 135-141.
84. Weems, J.M.; Yost, G.S. 3-Methylindole metabolites induce lung CYP1A1 and CYP2F1 enzymes by AhR and non-AhR mechanisms, respectively. Chem. Res. Toxicol., 2010, 23(3), 696-704.
85. Carlson, J.R.; Yokoyama, M.T.; Dickinson, E.O. Induction of pulmonary edema and emphysema in cattle and goats with 3-methylindole. Science, 1972, 176(4032), 298-299.
86. Weems, J.M.; Cutler, N.S.; Moore, C.; Nichols, W.K.; Martin, D.; Makin, E.; Lamb, J.G.; Yost, G.S. 3-Methylindole is mutagenic and a possible pulmonary carcinogen. Toxicol. Sci., 2009, 112(1), 59-67.
87. Jaworska, K.; Huc, T.; Samborowska, E.; Dobrowolski, L.; Bielin-ska, K.; Gawlak, M.; Ufnal, M. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS One, 2017, 12(12), e0189310.
88. Hubbard, T.D.; Murray, I.A.; Perdew, G.H. Indole and tryptophan metabolism: Endogenous and dietary routes to ah receptor activation. Drug. Metab. Dispos., 2015, 43(10), 1522-1535.
89. Romani, L.; Zelante, T.; De Luca, A.; Iannitti, R.G.; Moretti, S.; Bartoli, A.; Aversa, F.; Puccetti, P. Microbiota control of a trypto-phan-AhR pathway in disease tolerance to fungi. Eur. J. Immunol., 2014, 44(11), 3192-3200.
90. Jin, U.H.; Lee, S.O.; Sridharan, G.; Lee, K.; Davidson, L.A.; Jayaraman, A.; Chapkin, R.S.; Alaniz, R.; Safe, S. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon recep-tor-dependent agonist and antagonist activities. Mol. Pharmacol., 2014, 85(5), 777-788.
91. Hubbard, T.D.; Murray, I.A.; Bisson, W.H.; Lahoti, T.S.; Gowda, K.; Amin, S.G.; Patterson, A.D.; Perdew, G.H. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci. Rep., 2015, 5, 12689.
92. Badawy, A.A. Kynurenine pathway of tryptophan metabolism: Regulatory and functional aspects. Int. J. Tryptophan Res., 2017, 10, 1178646917691938.
93. Baumgartner, R.; Forteza, M.J.; Ketelhuth, D.F.J. The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis. Cytokine, 2017, S1043-4666(17), 30259-30254.
94. Nagy, B.M.; Nagaraj, C.; Meinitzer, A.; Sharma, N.; Papp, R.; Foris, V.; Ghanim, B.; Kwapiszewska, G.; Kovacs, G.; Klepetko, W.; Pieber, T.R.; Mangge, H.; Olschewski, H.; Olschewski, A. Importance of kynurenine in pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol., 2017, 313(5), L741-L751.
95. Oxenkrug, G.F. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: The serotonin hypothesis revisited 40 years later. Isr. J. Psychiatry Relat. Sci., 2010, 47(1), 56-63.
96. Plitman, E.; Iwata, Y.; Caravaggio, F.; Nakajima, S.; Chung, J.K.; Gerretsen, P.; Kim, J.; Takeuchi, H.; Chakravarty, M.M.; Remington, G.; Graff-Guerrero, A. Kynurenic acid in Schizophrenia: A Systematic review and meta-analysis. Schizophr. Bull., 2017, 43(4), 764-777.
97. Jones, R.S. Tryptamine: A neuromodulator or neurotransmitter in mammalian brain? Prog. Neurobiol., 1982, 19(1-2), 117-139.
98. Tittarelli, R.; Mannocchi, G.; Pantano, F.; Romolo, F.S. Recreational use, analysis and toxicity of tryptamines. Curr. Neuropharmacol., 2015, 13(1), 26-46.
99. Brune, G.G.; Himwich, H.E. Indole metabolites in schizophrenic patients: Urinary excretion. Arch. Gen. Psychiatry, 1962, 6(4), 324-328.
100. Williams, B.B.; Van Benschoten, A.H.; Cimermancic, P.; Donia, M.S.; Zimmermann, M.; Taketani, M.; Ishihara, A.; Kashyap, P.C.; Fraser, J.S.; Fischbach, M.A. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host. Microbe., 2014, 16(4), 495-503.
101. Gershon, M.D.; Ross, L.L. Location of sites of 5-hydroxytryptamine storage and metabolism by radioautography. J. Physiol., 1966, 186(2), 477-492.
102. Mercado, C.P.; Kilic, F. Molecular mechanisms of SERT in platelets: Regulation of plasma serotonin levels. Mol. Interv., 2010, 10(4), 231-241.
103. Jonnakuty, C.; Gragnoli, C. What do we know about serotonin? J. Cell Physiol., 2008, 217(2), 301-306.
104. Fidalgo, S.; Ivanov, D.K.; Wood, S.H. Serotonin: From top to bottom. Biogerontology, 2013, 14(1), 21-45.
105. Sprince, H. Indole metabolism in mental illness. Clin. Chem., 1961, 7(3), 203-230.
106. Mileikovskii, Y.A. Excretion of catecholamines and tryptophan derivatives in schizophrenia. Neurosci. Behav. Physiol., 1979, 9(4), 325-328.
107. Challacombe, D.N.; Sandler, M.; Southgate, J. Decreased duodenal monoamine oxidase activity in coeliac disease. Arch. Dis. Child., 1971, 46(246), 213-215.
108. Challacombe, D.N.; Dawkins, P.D.; Baker, P. Increased tissue concentrations of 5-hydroxytryptamine in the duodenal mucosa of patients with coeliac disease. Gut, 1977, 18(11), 882-886.
109. Haverback, B.J.; Dyce, B.; Thomas, H. V. Indole metabolism in the malabsorption syndrome. N. Engl. J. Med., 1960, 262, 754-757.
110. Yano, J.M.; Yu, K.; Donaldson, G.P.; Shastri, G.G.; Ann, P.; Ma, L.; Nagler, C.R.; Ismagilov, R.F.; Mazmanian, S.K.; Hsiao, E.Y. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell, 2015, 161(2), 264-276.
111. Wurtman, R.J.; Axelrod, J.; Phillips, L.S. Melatonin synthesis in the pineal gland: Control by light. Science, 1963, 142(3595), 1071-1073.
112. Reiter, R.J.; Paredes, S.D.; Manchester, L.C.; Tan, D.X. Reducing oxidative/nitrosative stress: A newly-discovered genre for melatonin. Crit. Rev. Biochem. Mol. Biol., 2009, 44(4), 175-200.
113. Macchi, M.M.; Bruce, J.N. Human pineal physiology and functional significance of melatonin. Front. Neuroendocrinol., 2004, 25(3-4), 177-195.
114. Hersh, C.; Sisti, J.; Richiutti, V.; Schernhammer, E. The effects of sleep and light at night on melatonin in adolescents. Hormones (Athens), 2015, 14(3), 399-409.
115. Sanchez, A.; Calpena, A.C.; Clares, B. Evaluating the oxidative stress in inflammation: Role of melatonin. Int. J. Mol. Sci., 2015, 16(8), 16981-17004.
116. Fernandez, A.; Ordonez, R.; Reiter, R.J.; Gonzalez-Gallego, J.; Mauriz, J.L. Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. J. Pineal. Res., 2015, 59(3), 292-307.
117. Altun, A.; Ugur-Altun, B. Melatonin: Therapeutic and clinical utilization. Int. J. Clin. Pract., 2007, 61(5), 835-845.
118. Sharma, S.; Singh, H.; Ahmad, N.; Mishra, P.; Tiwari, A. The role of melatonin in diabetes: Therapeutic implications. Arch. Endocrinol. Metab., 2015, 59(5), 391-399.